Therapeutic Drug Monitoring

Breakthrough technology to enhance monoclonal antibody-based treatment

Labelled Ipilimumab 13C15N

Application

Absolute quantification of Yervoy® or its biosimilars

Specific labelling

Arginine: 13C6,15N4, >99%

Lysine: 13C6,15N2, >99%

10 µg     ->    650 €      Quantity  

You must sign in or create an account to order this product

Description
Datasheet
Price

Ipilimumab, a recombinant human monoclonal antibody (IgG1 kappa immunoglobin), is an antineoplastic agent developed by Bristol-Myers Squibb and Medarex for the treatment of unresectable or metastatic melanoma in adults. The average weight of Ipilimumab is 148kDa. The labelled Ipilimumab-like stable isotope labelled standard is suited for quantification of Ipilimumab in human serum samples.

 

The mAb-like technology is patented.